Mymetics Corp (MYMX)

[Work Harder]

Cited By

General significance

By genetic modification, we were able to design a better-controlled and more stable vaccine candidate, which is an essential and important criterion for any process and manufacturing of biologics or drugs for human use.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788321/citedby/

Author contributions

WHC conceived the study, designed and performed experiments, interpreted data, and wrote the manuscript; JW performed experiments and interpreted data; RTK, RA, ZL, JL, LV, CP, BK, MJV, ACAL, and JAR performed experiments; JP participated in interpreting data, reviewed/edited the manuscript; PMG reviewed/edited the manuscript and effected logistics and supervision; US reviewed/edited the manuscript; BZ reviewed/edited the manuscript; PJH reviewed/edited the manuscript; MEB reviewed/edited the manuscript US, BZ, PJH, and MEB also provided scientific guidance on the project.

Declaration of Competing Interest

The authors declare that Baylor College of Medicine recently licensed the RBD219-N1C1 technology to an Indian manufacturer for further development. The research conducted in this paper was performed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was supported by the following funding sources: Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, USA; Fifth Generation, Inc. (Tito's Handmade Vodka), USA; JPB Foundation, USA, National Institute of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAHID), USA, Grant number AI14087201); and Texas Children's Hospital Center for Vaccine Development Intramural Funds, USA. We also would like to thank PATH Center for Vaccine Innovation and Access (Seattle, WA, USA) for their guidance as well as technical and intellectual support.

https://www.texaschildrens.org/departments/vaccine-development/our-team